



## Using age-stratified incidence data to examine the transmission consequences of pertussis vaccination



J.C. Blackwood <sup>a,\*</sup>, D.A.T. Cummings <sup>b</sup>, S. Iamsirithaworn <sup>c</sup>, P. Rohani <sup>d,e,f</sup>

<sup>a</sup> Department of Mathematics and Statistics, Williams College, Williamstown, MA 01267, USA

<sup>b</sup> Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA

<sup>c</sup> Bureau of Epidemiology, Ministry of Public Health, Nonthaburi, Thailand

<sup>d</sup> Odum School of Ecology, University of Georgia, Athens, GA 30606, USA

<sup>e</sup> Department of Infectious Diseases, School of Veterinary Medicine, University of Georgia, Athens, GA 30606, USA

<sup>f</sup> Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA

### ARTICLE INFO

#### Article history:

Received 1 July 2015

Received in revised form 9 February 2016

Accepted 16 February 2016

Available online 19 March 2016

#### Keywords:

Disease transmission

Epidemiology

Pertussis

Mathematical model

Immunity

### ABSTRACT

Pertussis is a highly infectious respiratory disease that has been on the rise in many countries worldwide over the past several years. The drivers of this increase in pertussis incidence remain hotly debated, with a central and long-standing hypothesis that questions the ability of vaccines to eliminate pertussis transmission rather than simply modulate the severity of disease. In this paper, we present age-structured case notification data from all provinces of Thailand between 1981 and 2014, a period during which vaccine uptake rose substantially, permitting an evaluation of the transmission impacts of vaccination. Our analyses demonstrate decreases in incidence across all ages with increased vaccine uptake – an observation that is at odds with pertussis case notification data in a number of other countries. To explore whether these observations are consistent with a rise in herd immunity and a reduction in bacterial transmission, we analyze an age-structured model that incorporates contrasting hypotheses concerning the immunological and transmission consequences of vaccines. Our results lead us to conclude that the most parsimonious explanation for the combined reduction in incidence and the shift to older age groups in the Thailand data is vaccine-induced herd immunity.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Pertussis, or whooping cough, is a highly infectious respiratory disease that remains a major public health concern (Wood and McIntyre, 2008; Domenech de Celles et al., 2016). Despite the initial success of pediatric vaccination programs, pertussis is currently responsible for an estimated 300,000 deaths per year worldwide (Crowcroft and Pebody, 2006). In addition, it has undergone a resurgence in many countries – including the United States (Rohani and Drake, 2011; Magpantay and Rohani, 2015) – despite maintaining high levels of vaccine uptake (Wood and McIntyre, 2008). While many plausible mechanisms driving these dynamics has been proposed (Jackson and Rohani, 2014; Domenech de Celles et al., 2016), the protective immunity elicited by both whole cell (wP) and acellular (aP) vaccines has long been questioned (Preston and Stanbridge, 1972; Blennow et al., 1988; Ausiello and Cassone, 2014). The absence of a reliable serological marker for protection

has meant that much of the discussion regarding the consequences of vaccination for immunity have focused on epidemiological patterns (Lavine et al., 2011).

The ability of whole cell vaccines to prevent pertussis transmission has been discussed for more than fifty year (Preston, 1965) and was famously called into question by Fine and Clarkson (1982), who argued based on patterns of periodicity in pertussis incidence that whole cell vaccines likely prevented disease rather than transmission. If true, this would lead to significant silent circulation of pertussis (Águas et al., 2006; Kretzschmar et al., 2010), posing a major threat to unvaccinated or partially immunized infants, who are at highest risk of pertussis-related complications and death. More recently, the debate regarding the mechanisms behind pertussis resurgence and the potential role played by has centered on acellular vaccines (Aoyama et al., 1985; Ausiello and Cassone, 2014; Domenech de Celles et al., 2014). Two modeling studies have concluded that pertussis resurgence may be the natural consequence of widespread switch to the aP vaccine (Gambhir et al., 2015) and its inability to generate protective immunity (Edwards, 2014; Althouse and Scarpino, 2015). This conclusion is supported by animal transmission models, in baboons (Warfel et al., 2014) and

\* Corresponding author. Tel.: +1 4135972424.

E-mail address: [jcb5@williams.edu](mailto:jcb5@williams.edu) (J.C. Blackwood).

mice (Smallridge et al., 2014), where the experimental challenge of aP-vaccinated animals indicates the potential for a transmissible infection.

To better understand the extent of the cross-over between individual-level animal challenge experiments to population-level pertussis incidence in humans and the consistency between epidemiological evidence in different countries, we examined incidence reports from Thailand. Specifically, we scrutinized age-stratified incidence data from different provinces in Thailand from 1981 to 2000. During this period, vaccine uptake systematically increased from ~26% in the early 1980s to greater than 95% by mid-1990s. We explored the epidemiological consequences of this vaccine ramp-up to assess the protective effects of wP vaccination. We paid particular attention to changes in incidence among “high risk” groups – such as unvaccinated infants – as uptake increased. Epidemiological theory predicts that vaccination programs that successfully protect vaccinees from infection should induce herd immunity, thereby minimizing transmission to unprotected high risk groups (Gay and Miller, 2000). Tracking incidence in these age-groups is therefore an essential component to quantifying the success of vaccination in reducing circulation (Keeling and Rohani, 2008; Domenech de Celles et al., 2016). For this reason, we also examined pertussis incidence reports from 2003 to 2014 in infants younger one month and those between 1 and 12 months.

The analyses of age-incidence patterns were allied to two age-structured transmission models, which were used to distinguish among competing hypotheses about the role of vaccine-protection as a driver of observed age-structured incidence (ex. Riolo et al., 2013; Lavine et al., 2011; Rohani et al., 2010). We challenged these models to capture the qualitative epidemiological transition observed in Thailand when contrasting assumptions were made regarding the immunological impacts of infant immunization. In previous analyses, we reported that there is an increase in herd immunity with vaccine uptake in Thailand and we supported these claims through the use of statistical inference to select a best-fitting model of pertussis dynamics (Blackwood et al., 2013). However, that analysis primarily considered the aggregate data independent of age. Here, we provide additional corroboration via a study of age-structured dynamics. Consistent with our prior analyses, we find empirical support for increased herd immunity with vaccine uptake in Thailand, a finding that is re-inforced by our transmission modeling.

## 2. Pertussis incidence data, 1981–2000

Thailand adopted the National Expanded Programme on Immunization (EPI) in 1977 for infant vaccination. Initially, two doses of the diphtheria–tetanus–pertussis (DTP) whole cell vaccine was administered until a third dose was added to the schedule in 1982 (Bhunbhu, 1989). Beginning in 1992, the schedule included 5 doses of DTP at 2, 4, 6, and 18 months with the final booster dose at 4–6 years. The whole cell vaccine was used exclusively until 1998. Since then, the DTP-HiB has been favored in government clinics and the acellular vaccine (DTaP) in private clinics. We obtained the corresponding annual national vaccine uptake estimates for 1981–1996 and 1999 from the Vaccine Coverage Survey of Thailand. Missing years (1997–1998, 2000) were assumed to have attained the same uptake as the most recently reported year.

Annual case notification data from each of Thailand's 72 provinces between 1981 and 2000 were obtained from the Ministry of Public Health (Bureau of Epidemiology, 1981–2000). From 1981 to 2000, the case notification data were also available annually for the following age groups: under 1 year, 1–4, 5–9, 10–14, 15–24, 25–34, 35–44, 45–54, 55–64, and older than 65 years of age. In 1985 these data were also available for one-year age groups up to age

seven. In our analysis we assumed the age of cases were uniformly distributed between all ages within each age group. We obtained age-stratified population data for 1980, 1990, and 2000 from the National Statistical Office of Thailand censuses and log-linear fits between census years were used to estimate annual population sizes from 1981 to 2000 (National Statistical Office of Thailand, 1980, 1991, 2001).

## 3. Age-structured incidence dynamics


In this section, we present the age-structured incidence data from Thailand during the time period 1981–2000. To paint a general picture of pertussis in Thailand, in Fig. 1A we present aggregated monthly incidence in addition to the annual vaccine uptake. Three clear epidemics are observed in 1981, 1982, and 1983 followed by a rapid decline from 1984 to 1990 and stable low incidence throughout the 1990s. These dynamics coincide with the rapid rise in vaccine uptake, which consistently exceeds 95% beginning in 1996.

Fig. 1A also includes two shaded regions: 1981–1983 (gray) and 1996–2000 (green). These two time periods display dramatically different incidence patterns corresponding to changes in vaccine uptake. Namely, incidence was highest from 1981 to 1993 when vaccine uptake was the lowest, and incidence remained very low from 1996 to 2000 when vaccine uptake remained above 95%. A comparison of the age-specific incidence patterns during these two “eras” is presented in Fig. 1B, depicting the percentage of reported cases attributed to five different age groups (under 1 year, 1–4, 5–9, 10–15, and 15+ years). The figure indicates a shift in incidence to older age groups in the later era.

To observe the age-stratified dynamics at a finer temporal resolution, in Fig. 1C we display the percentage of annual cases in four age classes. During the early through mid-1980s, the age distribution of cases remains relatively stable with between 13% and 23% of all cases attributed to infants. The percent of cases in infants then rises briefly and drops again in the early 1990s. The decline in the percent of cases in infants coincides with a dramatic increase in vaccine uptake. While this is indicative of reduced transmission to infants – who are more susceptible to disease because they are less likely to be fully immunized against pertussis – it should be noted that the incidence is very low throughout the 1990s. As a consequence, variability in the age-distribution is to be expected and such variation is indeed observed during the years post-1995.

To determine whether these observations are consistent at finer spatial resolutions, Fig. 2B–G replicates Fig. 1B for each of the six distinct geographic regions of Thailand (as developed by the National Geographical Committee in 1978). In Fig. 2B–G, the percent of cases in each age group from 1981 through 1983 are represented by gray bars and the percent of cases in each age group from 1996 to 2000 are in color. The bars are colored by region, and Fig. 2A provides a map of Thailand such that the provinces in each region are colored accordingly. These data are consistent with those for Thailand as a whole (Fig. 1B), with a higher percentage of cases attributed to older age classes during 1996–2000. While the Western (Fig. 2C, pink) region appears to contradict this observation, it only accounts for 5.3% of the total cases in Thailand and therefore has minimal impact on the overall age-structured dynamics in the country as a whole.

Previous work has shown that an increase in the mean age of infection may correspond to decreasing transmission to infants (e.g. Skowronski et al., 2002). We therefore estimated the mean age of infection for the early (1981–1983) and late (1996–2000) vaccine eras, assuming that cases are uniformly distributed within age classes (see Supplementary information for details). To test



**Fig. 1.** (A) Monthly incidence in Thailand (black) and the corresponding vaccine uptake (red) from 1981 through 2000. These colors match the data as shown in (B) of this figure. (B) The percent of cases in five different age groups during the time period 1981–1983 (gray bars) compared to the time period 1996–2000 (green bars). Note that the shading in (A) of this figure matches in bars in (B). Notice that between time periods, the distribution of cases shifts so that there is a greater percentage of cases in adolescents and adults. (C) Percent of annual cases per year in four different age groups. The age distribution stays relatively constant until 1988 and then the percent of cases in individuals ages 5+ tends to increase for the remainder of the time series.


whether the mean age at infection significantly increased from the early to the late era, we bootstrapped the ages of the case reports. The resulting distribution of 10,000 bootstrap samples for each region revealed a significant increase of 4.31, 2.07, 1.93, and 2.87 years, respectively, for Regions 3–6. With the exception of Region 5, the respective 95% CI for each vaccine era were completely non-overlapping. In contrast, there was no increase in the mean ages of infection in Regions 1 and 2 (details and figures provided in [Supplementary information](#)). However, we note that Regions 1 and 2 account for only 15% of the total cases reported in Thailand. For the purposes of comparison, we performed the same analysis on the aggregated data at the national level. We estimated that the nationwide mean age of infection increased from 5.44 years in 1981–1983 to 7.77 years in 1996–2000. The resulting distribution of 10,000 bootstrap samples displays a shift in the mean age of infection between the vaccine eras ([Fig. 4B](#)). In fact, the 95% CIs are completely non-overlapping ((5.35, 5.52) years for the first vaccine era and (7.12, 8.65) for the later era). Therefore, there is a clear increase in the mean age of infection that is driven by the incidence dynamics in Regions 1–4.

Finally, an alternative way to visualize the impact of vaccination on age-structured incidence is presented in [Fig. 4A](#). Here, the age-specific incidence is shown when vaccine uptake is relatively low (<46%, in red) as well as when it is high (>95%, in blue). This figure displays the average of the aggregate incidence across Thailand for each vaccine era. Under the assumption that

case reports were drawn from a binomial distribution, 95% CIs are found using the Fisher information. Here, the increase in vaccine uptake clearly corresponds to a decline incidence across all ages, especially in infants. In particular, there were an average of 571 cases in infants per year during 1981–1983 compared to an average of 13.2 cases per year during 1996–2000. While these averages are computed at the national level, we demonstrate that the decrease in cases in infants is consistent across the provinces of Thailand (see [Supplementary information](#)). [Fig. 4A](#) is consistent with declining pertussis transmission following vaccination. We assume that reporting is consistent across all ages, so while biases in reporting may contribute to the dynamics, we argue that it is very unlikely that reporting alone accounts for the observed dramatic shift in age structure.

#### 4. Modeling age-structured pertussis dynamics

While the age stratified incidence data are strongly suggestive of decreased transmission with increased vaccination, they do not eliminate the possibility that vaccines prevent symptomatic disease but not transmission ([Fine and Clarkson, 1982](#); [Águas et al., 2006](#)). Ideally, this issue would be resolved by statistical inference methods applied to a mechanistic transmission model (e.g., [Blackwood et al., 2013](#); [Gambhir et al., 2015](#)). However, the absence of age-stratified data more highly resolved than annual incidence precludes such an analysis. We therefore formulated a simple



**Fig. 2.** The percent of cases in age group from 1981 to 1983 (light gray bars) as compared to the percent of cases in each age group from 1996–2000 (colored bars). The color representing 1996–2000 in (B)–(G) correspond to one of the six distinct geographic regions of Thailand: (B) Northern, (C) Western, (D) Central, (E) Northeastern, (F) Eastern, and (G) Southern region. (A) provides a map of Thailand that is colored according to region. With the exception of the Western region (which only accounts for 5.3% of the total cases in Thailand), the percentage of cases in older age groups increases in all regions in the later time period.

age-structured mathematical model (Rohani et al., 2010) for use as a heuristic device: to explore the dynamical consequences of alternative assumptions regarding vaccine impact and their parsimony with the Thai data. For the purposes of direct comparison with the Thai data (Fig. 4A), we explored five age classes: <1, 1–4, 5–9, 10–14, and >15 years old.

Our compartmental transmission models were constructed using the SIR (susceptible–infected–recovered) paradigm (Anderson and May, 1991; Keeling and Rohani, 2008). Consistent with estimates obtained via likelihood-based statistical inference of the Thai data (Blackwood et al., 2013), we assumed naturally acquired immunity to be lifelong. We assumed newborns (<1 year) to be susceptible to pertussis. Upon entering the next age class, with probability  $p$ , an infant may be immunized. In the first model, we assumed that both immunization and naturally acquired infections provide lifelong protection against pertussis infection, yielding a simple SIR model. In the second model, we assumed that only naturally acquired infections results in lifelong immunity. To examine the consequences of vaccine-induced protection against infection versus disease, we assumed immunization to provide a temporary period of protection against infection after which individuals experience reduced susceptibility to disease, but not infection. Specifically, this model included three additional classes: a vaccinated and fully protected class  $V$  (with mean duration of protection  $1/\rho$  years), a vaccinated but susceptible to infection class  $S^V$ , and a vaccinated infected class ( $I^V$ ) in which individuals were assumed to be asymptomatic but otherwise function identically to infectious individuals with no history of vaccination. In this model, only symptomatic infections ( $I$  individuals) were reported which allowed us to directly examine whether subclinical infections can explain the shift in the age structure of case notifications. We refer to this model as  $SIV_R$ .

For all age classes and both models, the force of infection – the *per capita* hazard of transmission experienced by susceptibles – due to individuals in the infected ( $I$ ) class is


$$\lambda_i = \sum_{j=1}^5 \beta_{ij} I_j, \quad (1)$$

where  $\beta_{ij}$  represents the transmission rate from individuals in the  $j$ th age class to members of the  $i$ th age class, and  $I_j$  is the proportion of the population infected in each age group  $j$ , as specified above. The  $SIV_R$  additionally had an associated force of infection arising from individuals in the infected class that can transmit without being observed. We denoted this by  $\lambda_i^V$ :

$$\lambda_i^V = \sum_{j=2}^5 \beta_{ij}^V I_j^V, \quad (2)$$

where  $I_j^V$  is the proportion of individuals who are infected but were previously vaccinated in each age group  $j$ .

To analyze the SIR and  $SIV_R$  models, we assumed two contrasting patterns of age-specific contacts: (i) homogeneous mixing and (ii) age-assortative contact structure, as reported from the POLYMOD study of several European countries (Mossong et al., 2008). The results for the two different assumptions on contact structure were similar, so the results using the POLYMOD contact matrix are presented in *Supplementary information*. The basic reproduction ratio,  $R_0$ , set to equal 16 in both models. The models were simulated for levels of vaccine uptake ranging from 46% to 95%, as observed in Thailand. To quantify the age-stratification of transmission, we obtained the equilibrium prevalence in each age class (i.e.,  $I_i^*/n_i$ , where  $n_i$  is the proportion of the population in age



**Fig. 3.** Schematic representation of the age-structured models: the SIR model is the schematic on the upper panel and the SIV/R model is on the lower panel. Full model descriptions are provided in Supplementary information.


class  $i$ ). A schematic of each model is provided in Fig. 3 and the models are fully described in Supplementary information.

The age distribution of incidence predicted from the SIR model and the SIV/R model are displayed in Fig. 4C. The observed changes in the Thailand data were well-captured by the SIR model (dashed lines) with a incidence dramatically reduced across all age classes when vaccine uptake is increased to 95%. In contrast, under the assumption that vaccine prevents disease but not transmission (the SIV/R model), incidence is lowered in older age groups but remains high in unvaccinated infants.


To determine the sensitivity of the dynamics of the SIV/R model to vaccine uptake, we ran the model for several vaccine uptake levels. As shown in Fig. 4C, incidence in all age classes decreased as vaccine uptake increased, except incidence in the infant class which remains unchanged. To determine whether a longer duration of temporary immunity following vaccination can qualitatively produce changes in age incidence consistent with the observed case notification data, we also varied the number of years spent in the protected vaccinated class ( $1/\rho$ ) while holding vaccine uptake at 95% (indicated by blue on the colormap). While a long duration of immunity (up to  $1/\rho = 100$  years) yields lower levels of incidence among infants, these reductions do not achieve comparable levels of the decline observed in data. This qualitative analysis is consistent with the interpretation that vaccination effectively reduces pertussis transmission (Blackwood et al., 2013), with the SIR model providing the most parsimonious explanation of the data. The details of age-specific patterns of contacts did not affect our qualitative conclusions.

## 5. Contemporary pertussis incidence: 2003–2014

Our analyses of incidence data from 1981 to 2000 support the conclusion that vaccination in Thailand has reduced the transmission of pertussis. However, in many countries, a honeymoon effect has been observed whereby the initial impact of high vaccine coverage has been to markedly reduce incidence only for a rebound at a later date (McLean and Anderson, 1988; Rohani and Drake, 2011; Riolo et al., 2013; Magpantay et al., 2014; Magpantay



**Fig. 4.** (A) Mean age structure of aggregated annual case notifications in Thailand with vaccine uptake of  $<46\%$  (years 1981–1983, red) and high vaccine uptake of  $>95\%$  (years 1996–2000, blue). Under the assumption that case reports are drawn from a binomial distribution, shading indicates 95% CI using the Fisher information. (B) The distribution of 10,000 bootstrap samples of the mean age of infection ( $p < 46\%$  in gray,  $p > 95\%$  in green). The sample means are 5.44 and 7.77 years, respectively with 95% CI of (5.35, 5.52) and (7.12, 8.65). Results from the SIV/R model assuming homogeneous mixing are displayed in (C) as the equilibrium prevalence by age group,  $I_a^*/n_i$ , where  $n_i$  is the fraction of the total population in age group  $i$ . Prevalence is corrected to account for the difference between the modeled infectious period (21 d) versus actual case notifications which are reported monthly. This is shown for various levels of vaccine uptake while holding the duration of immunity  $1/\rho$  at one year (right side of colormap circle) and various values  $1/\rho$  while holding vaccine uptake at 95% (left side of colormap circle). The dashed lines display the results from the age-structured SIR model for low (red) and high (blue) vaccine uptake.



**Fig. 5.** Age-stratified annual incidence from 2003 to 2014. Under the assumption that case reports are drawn from a binomial distribution, shading indicates 95% CI using the Fisher information. (A) Incidence in infants <28 d, (B) is 28 d – 1 year, and (C) is the mean incidence across all older age groups. In (C), 95% CIs are displayed as the bounds that fall farthest from the mean across all age groups in each year.

and Rohani, 2015). To examine the contemporary transmission of pertussis in Thailand, we depict, in Fig. 5, age-stratified pertussis incidence from 2003 to 2014. These data indicate that pertussis incidence remains very low, at levels comparable to those displayed in Fig. 4A corresponding to vaccine uptake >95%. The contemporary data are especially informative regarding transmission dynamics since they include incidence among infants <28 days old, who are too young to be immunized. Hence, any resurgence in pertussis transmission would be expected to result in an increasing trend in incidence among this age group. Indeed, incidence remains very low and in half of the years from 2002 to 2014 there are no reported cases in this age class. We submit that the absence of any rising trend, together with the rarity of pertussis in young infants, may be taken as additional support for vaccine-induced herd immunity in Thailand.

## 6. Discussion

Pertussis incidence has continued to rise over the last couple of decades in many developed countries in spite of longstanding vaccination programs, some of which began as early as the 1940s (Bass and Stephenson, 1987; Güriş et al., 1999). Understanding the drivers of this resurgence is becoming increasingly critical as case reports continue to rise. For example, in 2012 the United States had 48,277 cases reported to the World Health Organization – the most cases in a given year since 1959 and substantially higher than the number of cases reported in the epidemic of 2010 (27,550) (Clark, 2014; World Health Organization, 2014). A central question that has persisted for more than three decades concerns the transmission consequences of vaccines, and specifically whether they merely protect against disease and not infection. These differences have significant impacts on the design of successful booster vaccination programs (Rohani et al., 2015). In this paper, we returned to this issue by taking advantage of long-term age-stratified pertussis incidence records in Thailand allied to contrasting hypotheses regarding vaccine impacts formulated within mathematical transmission models.

Much of the recent pertussis vaccines literature has focused on the role of the acellular vaccines (DTaP) (Aoyama et al., 1985; Ausiello and Cassone, 2014; Domenech de Celles et al., 2014; Warfel et al., 2014; Smallridge et al., 2014). In contrast, in Thailand the

whole cell vaccine (DTwP) was exclusively used until 1998 after which a combination of the acellular and whole cell vaccines have been in use. Our examination of age-structured case notification data from different regions of Thailand over the period 1981–2000 indicated a substantial decrease in incidence as vaccine uptake increased. Although much of these data correspond to the period in which DTwP was the only vaccine used (1981–1998), incidence remained very low in Thailand from 2003 to 2014 – with only 14 cases reported in 2014.

While the data appear to paint a clear picture of a rise in herd immunity, it is plausible that alternative mechanisms may yield a similar age-specific profile of cases. If vaccination simply prevents clinical symptoms rather than transmission, the decrease in incidence could be the natural result of a greater number of undiagnosed asymptomatic cases. To parse these alternatives, we analyzed two age-structured transmission models. The first model assumed that vaccination protects from infection (the age-structured SIR model) whereas the second, and more complex, model assumed that following temporary vaccine-derived immunity, individuals can acquire an asymptomatic infection that goes unreported (the SIV/R model). The resulting age distribution of incidence in each of these models is found for both high and low levels of vaccine uptake and compared to the corresponding age-structure of the data. While the SIV/R model accurately captured lowered incidence in older age groups following high levels of vaccine uptake, it failed to capture the substantial decline in incidence in infants as observed in the data. In contrast, the simple age-structured SIR model accurately predicted substantially lowered incidence across all age groups, including infants. To assess the robustness of our conclusions, we determined the sensitivity to the SIV/R model to various levels of vaccine uptake ranging from 46% to 95%. Further, we allowed the duration of temporary immunity provided by vaccination to range from one to 100 years. While increasing the duration of temporary immunity caused a decrease in incidence in infants with high levels of vaccine uptake, all parameter values failed to reproduce the dramatic decline in incidence in infants as observed in the data. Further, this analysis was performed for both homogeneous mixing of contacts and non-homogeneous mixing; both analyses yielded qualitatively similar results.

Through combining age-structured incidence data and mathematical models, our findings point to a rise in herd immunity

as a result of a decline in transmission following vaccination in Thailand. We submit that these findings provide a useful counterpoint to the increasing reliance on serology. For instance, Wanlapakorn et al. (2016) have recently presented age-stratified serological data from Thailand indicating declining antibody levels with age. Despite the uncertainty associated with the interpretation of pertussis toxin antibodies as a correlate of protection, the authors recommend “a booster dose during adolescence should be considered in order to reduce the incidence of pertussis disease”. Our examination of pertussis incidence reports lead us to question this inference. Substantial pertussis circulation among adults and adolescents would inevitably lead to increased incidence among infants, especially those too young to be immunized (Gay and Miller, 2000; Domenech de Celles et al., 2016). In contrast, the very low incidence in infants in high-vaccine coverage periods is a strong indicator of herd immunity.

## Acknowledgements

We thank an anonymous reviewer for their helpful feedback on earlier drafts of this manuscript. This work is supported by the Research and Policy in Infectious Disease Dynamics program of the Science and Technology Directorate, Department of Homeland Security, the Fogarty International Center, National Institutes of Health and by a research grant from the National Institutes of Health (1R01AI101155) and by MIDAS, National Institute of General Medical Sciences U54-GM111274.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.epidem.2016.02.001>.

## References

- Águas, R., Gonçalves, G., Gomes, M.G.M., 2006. Pertussis: increasing disease as a consequence of reducing transmission. *Lancet Infect. Dis.* 6, 112–117.
- Althouse, B.M., Scarpino, S.V., 2015. Asymptomatic transmission and the resurgence of *Bordetella pertussis*. *BMC Med.* June, 1–12.
- Anderson, R.M., May, R.M., 1991. *Infectious Diseases of Humans*. Oxford University Press, New York.
- Aoyama, T., Murase, Y., Kato, T., Iwata, T., 1985. Efficacy of an acellular pertussis vaccine in Japan. *J. Pediatr.* 107 (2), 180–183.
- Ausiello, C.M., Cassone, A., 2014. Acellular pertussis vaccines and pertussis resurgence: revise or replace? *mBio* 5 (April (3)), e01339-14-e01339-14.
- Bass, J.W., Stephenson, S.R., 1987. The return of pertussis. *Pediatr. Infect. Dis. J.* 6, 141–144.
- Bhunbhu, T., 1989. Expanded programme on immunization in Thailand. *Rev. Infect. Dis.* 11 (Suppl. 3), S514–S517.
- Blackwood, J.C., Cummings, D.A.T., Broutin, H., Iamsirithaworn, S., Rohani, P., 2013. Deciphering the Impacts of Vaccination, Demographic Transition and Immunity on Pertussis Epidemiology in Thailand. *Proc. Natl. Acad. Sci.* 110 (February (23)), 20837–20842.
- Blennow, M., Olin, P., Granström, M., Bernier, R.H., 1988. Protective efficacy of a whole cell pertussis vaccine. *Br. Med. J. (Clin. Res. Ed.)* 296 (June (6636)), 1570–1572.
- Bureau of Epidemiology, 1981–2000. Annual Epidemiological Surveillance Report. Ministry of Public Health of Thailand, Nonthaburi, Thailand.
- Clark, T.A., 2014. Changing pertussis epidemiology: everything old is new again. *J. Infect. Dis.* 209 (7), 978–981.
- Crowcroft, N.S., Pebody, R.G., 2006. Recent developments in pertussis. *Lancet* 367, 1926–1936.
- Domenech de Celles, M., Magpantay, F.M.G., King, A.A., Rohani, P., 2016. The pertussis enigma: reconciling epidemiology, immunology and evolution. *Proc. R. Soc. Lond. – Biol. Sci.* 283 (January (1–10)).
- Domenech de Celles, M., Riolo, M.A., Magpantay, F.M.G., Rohani, P., King, A.A., 2014. Epidemiological evidence for herd immunity induced by acellular pertussis vaccines. *Proc. Natl. Acad. Sci. U. S. A.* 111 (February (7)), E716–E717.
- Edwards, K.M., 2014. Unraveling the challenges of pertussis. *Proc. Natl. Acad. Sci.* 111 (2), 575–576.
- Fine, P.E.M., Clarkson, J.A., 1982. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. *Lancet* 1, 666–669.
- Gambhir, M., Clark, T.A., Cauchemez, S., Tartof, S.Y., Swerdlow, D.L., Ferguson, N.M., 2015. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. *PLoS Comput. Biol.* 11 (April (4)), e1004138.
- Gay, N.J., Miller, E., 2000. Pertussis transmission in England and Wales. *Lancet* 355 (9214), 1553–1554.
- Gürüş, D., Strelbel, P.M., Bardenheier, B., Brennan, M., Tachdjian, R., Finch, E., Wharton, M., Livengood, J.R., 1999. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. *Clin. Infect. Dis.* 28, 1230–1237.
- Jackson, D., Rohani, P., 2014. Perplexities of pertussis: recent global epidemiological trends and their causes. *Epidemiol. Infect.* 142 (04), 672–684.
- Keeling, M.J., Rohani, P., 2008. *Modeling Infectious Diseases in Humans and Animals*. Princeton University Press, Princeton.
- Kretzschmar, M., Teunis, P.F.M., Pebody, R.G., 2010. Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries. *PLoS Med.* 7 (6), e1000291.
- Lavine, J.S., King, A.A., Bjørnstad, O.N., 2011. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. *Proc. Natl. Acad. Sci. U. S. A.*, <http://dx.doi.org/10.1073/pnas.1014394108>.
- Magpantay, F.M.G., Rohani, P., 2015. Dynamics of pertussis transmission in the United States. *Am. J. Epidemiol.* 181 (12), 921–931.
- Magpantay, F.G., Riolo, M.A., Domenech de Celles, M., King, A.A., Rohani, P., 2014. Epidemiological consequences of imperfect vaccines for immunizing infections. *SIAM Appl. Math.* 74 (6), 1810–1830.
- McLean, A.R., Anderson, R.M., 1988. Measles in developing countries. Part ii. The predicted impact of mass vaccination. *Epidemiol. Infect.*
- Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G.S., Wallinga, J., Heijne, J., Sadkowska-Todys, M., Rosinska, M., John Edmunds, W., 2008. Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLoS Med.* 5 (3), e74.
- National Statistical Office of Thailand, 1980. 1980 Census. Technical Report. National Statistical Office of Thailand, Bangkok.
- National Statistical Office of Thailand, 1991. 1990 Census. Technical Report. National Statistical Office of Thailand, Bangkok.
- National Statistical Office of Thailand, 2001. 2000 Census. Technical Report. National Statistical Office of Thailand, Bangkok.
- Preston, N.W., 1965. Effectiveness of pertussis vaccines. *Br. Med. J.* 2 (5452), 11.
- Preston, N.W., Stanbridge, T.N., 1972. Efficacy of pertussis vaccines: a brighter horizon. *Br. Med. J.* 3 (5824), 448.
- Riolo, M.A., King, A.A., Rohani, P., 2013. Can vaccine legacy explain the British pertussis resurgence? *Vaccine* 32, 5903–5908.
- Riolo, M.A., King, A.A., Rohani, P., 2013. Can vaccine legacy explain the British pertussis resurgence? *Vaccine* 31 (October (49)), 5903–5908.
- Riolo, M.A., Rohani, P., 2015. Combating pertussis resurgence: one booster vaccination schedule does not fit all. *Proc. Natl. Acad. Sci. U. S. A.* 112 (January (5)), E472–E477.
- Rohani, P., Zhong, X., King, A.A., 2010. Contact network structure explains the changing epidemiology of pertussis. *Science* 330, 982–985.
- Rohani, P., Drake, J.M., 2011. The decline and resurgence of pertussis in the US. *Epidemics* 3 (September (3–4)), 183–188.
- Skowronski, D.M., De Serres, G., MacDonald, D., Wu, W., Shaw, C., Macnabb, J., Champagne, S., Patrick, D.M., Halperin, S.A., 2002. The changing age and seasonal profile of pertussis in Canada. *J. Infect. Dis.* 185 (10), 1448–1453.
- Smallridge, W.E., Rollin, O.Y., Jacobs, N.T., Harvill, E.T., 2014. Different effects of whole-cell and acellular vaccines on *Bordetella* transmission. *J. Infect. Dis.* 209 (12), 1981–1988.
- Wanlapakorn, N., Ngaoivithunvong, V., Thongmee, T., Vichaiwattana, P., Vongpunsawad, S., Poovorawan, Y., 2016. Seroprevalence of antibodies to pertussis toxin among different age groups in Thailand after 37 years of universal whole-cell pertussis vaccination. *PLoS ONE* 11 (February (2)), e0148338.
- Warfel, J.M., Zimmerman, L.I., Merkel, T.J., 2014. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. *Proc. Natl. Acad. Sci.* 111 (2), 787–792.
- Wood, N., McIntyre, P., 2008. Pertussis: review of epidemiology, diagnosis, management and prevention. *Paediatr. Respir. Rev.* 9, 201–212.
- World Health Organization, 2014. WHO Vaccine Preventable Diseases Monitoring System: 2014 Global Summary,. Available from: [http://apps.who.int/immunization\\_monitoring/globalsummary/timeseries/tsincidencepertussis.html](http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencepertussis.html) (accessed 10.07.14).